180 related articles for article (PubMed ID: 22586512)
1. Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphoma.
Luminari S; Montanini A; Federico M
Hematol Rep; 2011 Oct; 3(3s):e4. PubMed ID: 22586512
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular adverse events associated with cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone with or without rituximab ((R)-CDOP) in non-Hodgkin's lymphoma: A systematic review and meta-analysis.
Lu B; Shen L; Ma Y; Qi J; Li Y; Wang Z; Han L; Zhong M
Front Pharmacol; 2022; 13():1060668. PubMed ID: 36532720
[No Abstract] [Full Text] [Related]
5. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors.
Schmitt CJ; Dietrich S; Ho AD; Witzens-Harig M
Ann Hematol; 2012 Mar; 91(3):391-7. PubMed ID: 21850390
[TBL] [Abstract][Full Text] [Related]
6. Liposomal encapsulated doxorubicin (Caelyx) in the treatment of relapsed aggressive non-Hodgkin's lymphoma: a phase II study.
Macpherson N; Belch A; Taylor M; Sutherland J; Czaykowski P; Connors J
Leuk Lymphoma; 2006 Jul; 47(7):1327-32. PubMed ID: 16923564
[TBL] [Abstract][Full Text] [Related]
7. Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand.
Visani G; Isidori A
Expert Rev Anticancer Ther; 2009 Mar; 9(3):357-63. PubMed ID: 19275512
[TBL] [Abstract][Full Text] [Related]
8. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines.
Rigacci L; Mappa S; Nassi L; Alterini R; Carrai V; Bernardi F; Bosi A
Hematol Oncol; 2007 Dec; 25(4):198-203. PubMed ID: 17654614
[TBL] [Abstract][Full Text] [Related]
9. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma.
Møller MB; Nielsen O; Pedersen NT
Histopathology; 2002 Oct; 41(4):322-30. PubMed ID: 12383214
[TBL] [Abstract][Full Text] [Related]
10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
11. The role of pixantrone in the treatment of non-Hodgkin's lymphoma.
Borchmann P; Schnell R
Expert Opin Investig Drugs; 2005 Aug; 14(8):1055-61. PubMed ID: 16050797
[TBL] [Abstract][Full Text] [Related]
12. [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients].
Moreno M; Sancho JM; Gardella S; Coll R; García O; Gallardo D; Ribera JM
Med Clin (Barc); 2010 Jan; 134(2):72-5. PubMed ID: 19913261
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma.
Wirt DP; Giles FJ; Oken MM; Solal-Celigny P; Beck JR
Leuk Lymphoma; 2001 Feb; 40(5-6):565-79. PubMed ID: 11426529
[TBL] [Abstract][Full Text] [Related]
14. Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age.
Heintel D; Skrabs C; Hauswirth A; Eigenberger K; Einberger C; Raderer M; Sperr WR; Knöbl P; Müllauer L; Uffmann M; Dieckmann K; Gaiger A; Jäger U
Ann Hematol; 2010 Feb; 89(2):163-9. PubMed ID: 19636553
[TBL] [Abstract][Full Text] [Related]
15. Pegylated liposomal doxorubicin as single-agent treatment of low-grade non-Hodgkin's lymphoma: a phase II multicenter study.
Di Bella NJ; Khan MM; Dakhil SR; Logie KW; Marsland TA; Weinstein RE; Mirabel MY; Asmar L
Clin Lymphoma; 2003 Mar; 3(4):235-40. PubMed ID: 12672273
[TBL] [Abstract][Full Text] [Related]
16. [Adriamycin (doxorubicin)].
Ogura M
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1331-8. PubMed ID: 11681238
[TBL] [Abstract][Full Text] [Related]
17. Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines.
Baech J; Hansen SM; Lund PE; Soegaard P; Brown PN; Haaber J; Jørgensen J; Starklint J; Josefsson P; Poulsen CB; Juul MB; Torp-Pedersen C; El-Galaly TC
Br J Haematol; 2018 Dec; 183(5):717-726. PubMed ID: 30406945
[TBL] [Abstract][Full Text] [Related]
18. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.
Aapro M; Bernard-Marty C; Brain EG; Batist G; Erdkamp F; Krzemieniecki K; Leonard R; Lluch A; Monfardini S; Ryberg M; Soubeyran P; Wedding U
Ann Oncol; 2011 Feb; 22(2):257-67. PubMed ID: 20956616
[TBL] [Abstract][Full Text] [Related]
19. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
20. The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma.
Zinzani PL; Federico M; Oliva S; Pinto A; Rigacci L; Specchia G; Tucci A; Vitolo U
Leuk Lymphoma; 2015 Jan; 56(1):12-25. PubMed ID: 24559287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
